Abstract
Lung cancer is a leading cause of cancer related death and more common in older people. Immunotherapy has improved efficacy compared to chemotherapy in non-small cell lung cancer (NSCLC). We aimed to review existing data on efficacy and adverse events (AEs) of single agent immunotherapy for NSCLC by age. We reported OS, progression-free survival (PFS) and AEs by age. Suitable results were meta-analysed using the random effects model. 1803 papers were screened, ten eligible papers identified, seven included in meta-analyses. Included individual papers did not demonstrate a difference in OS, PFS or AEs. Meta-analyses showed no significant difference in OS (HR: 1.03, 95% CI 0.92-1.15; p=0.58), PFS (HR 0.96, 95% CI: 0.92-1.01; p=0.15) or AEs (HR:1.01 95% CI:0.83-1.23; p=0.91) in older vs younger patients. Existing data on differences in efficacy and AEs of immunotherapy by age is largely observational and points to similar efficacy and adverse events by age.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal on Oncology and Radiotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.